Listed by the USPTO as NIEBAUER, RONALD T
Tech Center 1600 • Art Units: 1654 1658 1676 1691
This examiner grants 41% of resolved cases
NIEBAUER, RONALD T is assigned to tech center 1600 and art unit 1654. His profile covers 732 resolved cases and shows an allowance rate of 40.8%. The median time to allowance is 1319 days. Interview lift is 34.0%, suggesting that interviews have played a meaningful role in the reported allowance outcomes.
The principal applicants are Novartis AG, Genmont Biotech Incorporation, and Boston Scientific Corporation. The listed firms are QUARLES & BRADY LLP, Clark+Elbing LLP, and Muncy, Geissler, Olds & Lowe, P.C. This combination gives practitioners a focused view of the applicant and counsel mix appearing in the record. The allowance and timing measures support careful prosecution budgeting and early planning for substantive examiner engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18352345 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | Non-Final OA | NOVARTIS AG |
| 18449907 | IODINATED CROSSLINKED HYDROGELS AND METHODS OF FORMING THE SAME | Final Rejection | Boston Scientific Scimed, Inc. |
| 18037287 | PROTEIN HYDROGELS AND METHODS FOR THEIR PREPARATION | Final Rejection | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18246063 | POLYMERS AND NANOPARTICLE FORMULATIONS FOR SYSTEMIC NUCLEIC ACID DELIVERY | Final Rejection | The Johns Hopkins University |
| 18250406 | PEPTIDE TAG AND TAGGED PROTEIN CONTAINING SAME | Non-Final OA | IDEMITSU KOSAN CO.,LTD. |
| 18004104 | HUMAN RECOMBINANT ACE2-FC MUTANTS THAT DECOUPLE ANTI-SARS-COV-2 ACTIVITY FROM CARDIOVASCULAR EFFECTS | Final Rejection | Northwestern University |
| 18812726 | LONG ACTING GLP-1/GIP DUAL AGONISTS | Non-Final OA | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| 17323683 | CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 18604185 | ANNEXIN TO INHIBIT BACTERIA | Non-Final OA | University of Virginia Patent Foundation |
| 18620645 | METHODS FOR THE SYNTHESIS OF PEPTOIDS USING GREEN SOLVENTS | Non-Final OA | The Governing Council of the University of Toronto |
| 17617095 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | Non-Final OA | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy40.8% of resolved applications examined by Ronald T Niebauer were allowed (732 resolved cases), compared with 48.5% across Art Unit 1654 over the last five years.
This examiner's interview lift is +34.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ronald T Niebauer took 1,319 days on average from filing to allowance.
Ronald T Niebauer examines applications in Art Unit 1654 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
